HELX – Franklin Genomic Advancements ETF
Franklin Genomic Advancements ETF (HELX) is a Health ETF, issued by Franklin Templeton Investments, $22.5M in assets, 0.50% expense ratio.
Returns as of Oct 23, 2026: 1 week +4.6%, 1 year +25.1%.
Concentrates on companies relevant to genomic advancements, primarily in health care industries.
Top holdings
- GH – Guardant Health Inc, 7.3%
- NTRA – Natera Inc, 6.9%
- KRYS – Krystal Biotech Inc, 5.2%
- MEDP – Medpace Holdings Inc, 4.7%
- INSM – Insmed Inc, 4.0%
- BBIO – BridgeBio Pharma Inc, 3.9%
- 207940 – Samsung Biologics Co Ltd, 3.6%
- ADPT – Adaptive Biotechnologies Corp, 3.5%
- UTHR – United Therapeutics Corporation, 3.3%
- ALNY – Alnylam Pharmaceuticals Inc, 3.2%
- LGND – Ligand Pharmaceuticals Incorporated, 3.0%
- AZN – AstraZeneca PLC ADR, 2.8%
- TEM – Tempus AI, Inc. Class A Common Stock, 2.7%
- VRTX – Vertex Pharmaceuticals Inc, 2.6%
- LLY – Eli Lilly and Company, 2.6%
- EXAS – EXACT Sciences Corporation, 2.2%
- REGN – Regeneron Pharmaceuticals Inc, 2.2%
- CTVA – Corteva Inc, 2.0%
- BNTX – BioNTech SE, 2.0%
- IONS – Ionis Pharmaceuticals Inc, 1.9%
- WGS – GeneDx Holdings Corp., 1.9%
- GRAL – GRAIL, LLC, 1.7%
- ARGX – Argen-X, 1.5%
- NBIX – Neurocrine Biosciences Inc, 1.5%
- PTCT – PTC Therapeutics Inc, 1.4%